Quality of life in metastatic prostate cancer among men of lower socioeconomic status: feasibility and criterion related validity of 3 measures.
暂无分享,去创建一个
L. Sharp | J. Chmiel | C. Bennett | T. Kuzel | R. Fine | R. Nadler | S. Knight | R. Sharifi | E. Moran | M. Albers | R. Fine | R. B. Nadler | C. Bennett | Mary Albers
[1] K. Pienta,et al. Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. , 1997, Urology.
[2] L. Sharp,et al. Comparison of perspectives on prostate cancer: analyses of survey data. , 1997, Urology.
[3] J. Ware,et al. Health-related quality of life among patients with metastatic prostate cancer. , 1997, Urology.
[4] D. Matchar,et al. Treatment considerations for persons with metastatic prostate cancer: survival versus out-of-pocket costs. , 1997, Urology.
[5] D. Osoba,et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] C. Bennett,et al. Performance measurement in prostate cancer care: beyond report cards. , 1996, Urology.
[7] M. E. Smith,et al. The Department of Veterans Affairs medical care system and the people it serves. , 1996, Medical care.
[8] L. Figgs,et al. Differences in cancer incidence, mortality, and survival between African Americans and whites. , 1995, Environmental health perspectives.
[9] R H Brook,et al. Quality-of-life outcomes in men treated for localized prostate cancer. , 1995, JAMA.
[10] J. Holland,et al. Quality of life of patients with prostate cancer and their spouses. The value of a data base in clinical care , 1994, Cancer.
[11] D. Osoba,et al. Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] D. Osoba,et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.
[13] D. Tulsky,et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] J. Sharp. Expanding the definition of quality of life for prostate cancer , 1993, Cancer.
[15] H. Herr,et al. A comparison of the quality of life of patients with metastatic prostate cancer who received or did not receive hormonal therapy , 1993, Cancer.
[16] C. Sherbourne,et al. The MOS 36-Item Short-Form Health Survey (SF-36) , 1992 .
[17] A McMurray,et al. Measuring the quality of life of cancer patients: the Functional Living Index-Cancer: development and validation. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] D. Karnofsky,et al. The use of the nitrogen mustards in the palliative treatment of carcinoma. With particular reference to bronchogenic carcinoma , 1948 .
[19] Taylor Murray,et al. Cancer statistics, 1998 , 1998, CA: a cancer journal for clinicians.
[20] G. Murphy,et al. The national cancer data base report on prostate cancer , 1995 .
[21] H. Villavicencio. Quality of life of patients with advanced and metastatic prostatic carcinoma. , 1993, European urology.
[22] S. Fosså,et al. Quality of life in prostate cancer , 1992, The Prostate. Supplement.
[23] W. Ellis,et al. Advanced prostatic carcinoma. Early versus late endocrine therapy. , 1991, The Urologic clinics of North America.
[24] S. Fosså,et al. Quality of life and treatment of hormone resistant metastatic prostatic cancer , 1990 .
[25] A. Dobson,et al. Measuring the quality of life of cancer patients: a concise QL-index for use by physicians. , 1981, Journal of chronic diseases.